Core Insights - J. Michael Nauman has been elected as the next Chairman of Matthews International Corporation, effective after the 2026 Annual Meeting of Shareholders, succeeding Alvaro Garcia-Tunon [1][2] - Nauman brings over 35 years of experience in commercial, strategic, and financial roles, previously serving as President and CEO of Brady Corporation and Executive Vice President at Molex [2][3] - The transition in leadership is seen as pivotal for Matthews, with Nauman's technical expertise and M&A experience expected to drive sustainable growth and long-term value creation for the company [3] Company Overview - Matthews International Corporation operates through two main segments: Industrial Technologies and Memorialization, focusing on operational efficiency and long-term growth through innovation and strategic expansion [4] - The Industrial Technologies segment is a global innovator in precision technologies, while the Memorialization segment provides products such as memorials and cremation equipment to cemetery and funeral home customers [4] - The company has over 5,400 employees across 19 countries, committed to delivering high-quality products and services [4]

Core Points - ACCO Group Holdings Limited announced the partial exercise of the over-allotment option by underwriters, resulting in the sale of an additional 49,900 ordinary shares at US$4.00 per share, increasing total shares sold to 1,449,900 and gross proceeds to approximately US$5.80 million [1] - The ordinary shares began trading on the Nasdaq Capital Market on October 17, 2025, under the symbol "ACCL" [2] - The net proceeds from the offering will be used for expanding corporate services, incorporating generative AI features, establishing a presence in the U.S. market, enhancing the company's global brand, and general working capital [2] Offering Details - The offering was conducted on a firm commitment basis with Craft Capital Management LLC as the representative of the underwriters and Revere Securities LLC as an underwriter [3] - The offering was conducted under the Company's registration statement on Form F-1, which was declared effective by the SEC on September 30, 2025 [4] Company Overview - ACCO Group Holdings Limited is a multi-disciplinary corporate service provider based in Hong Kong, specializing in corporate secretarial and accounting services in Hong Kong and intellectual property registration services in Singapore [6] - The company serves a diverse clientele, including individual clients, small and medium-sized enterprises, and multinational corporations, offering tailored, technology-enhanced solutions [6]

Core Viewpoint - Genco Shipping & Trading Limited is enhancing its asset base and earnings capacity through the acquisition of two modern Newcastlemax vessels for $145.5 million, expected to be delivered in Q1 2026 [1][2]. Company Overview - Genco Shipping & Trading Limited is a U.S.-based drybulk shipping company focused on the global transportation of commodities, operating a fleet that includes Newcastlemax and Capesize vessels [4]. Acquisition Details - The company has agreed to acquire two 2020-built Newcastlemax vessels, which are fitted with scrubbers, for a total of $145.5 million [1]. - The acquisition will be funded through cash on hand and a drawdown from its revolving credit facility [1]. Financial Strategy - The total investment in modern fuel-efficient Capesize and Newcastlemax tonnage over the last two years will amount to $343 million, improving the age profile of the asset base and enhancing earnings and dividend capacity [2]. - The latest vessels will not require a special survey until 2030, allowing for maximized utilization during favorable market conditions [2]. Market Positioning - The acquisition aligns with the company's strategy to capitalize on positive supply and demand trends in the drybulk market, particularly in the Capesize and Newcastlemax sectors [2]. - Genco's financial strength positions the company to pursue growth opportunities while reducing debt and maintaining substantial dividends for shareholders [2].

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema f ...

Core Insights - Nano Dimension Ltd. reported significant financial results for Q3 2025, highlighting an 81% year-over-year revenue increase to $26.9 million, driven by the acquisition of Markforged [7][12] - The company is actively pursuing cost reduction initiatives, expecting total savings of approximately 10% to 15% based on adjusted operating expenses [6][8] - For the first time, the company provided financial guidance for Q4 2025, projecting revenue between $31.5 million and $33.5 million, with non-GAAP gross margins of 47% to 48.5% [10][11] Financial Performance - Q3 2025 revenue reached $26.9 million, up from $14.9 million in Q3 2024, with a gross margin of 30.3%, down from 48.0% year-over-year [7][12] - Year-to-date revenue for 2025 was $67.1 million, a 55.4% increase from $43.2 million in the same period of 2024 [7][12] - The net loss from continuing operations for Q3 2025 was $29.5 million, compared to a loss of $9.9 million in Q3 2024 [14][25] Cost Management and Share Repurchase - The company has repurchased approximately 10.1 million shares year-to-date for about $17.1 million, indicating confidence in its stock valuation [11][12] - Operating expenses for Q3 2025 totaled $41.3 million, with significant contributions from the acquisition of Markforged [12][25] Strategic Initiatives - A strategic alternative review is ongoing, led by Guggenheim Securities and Houlihan Lokey, aimed at maximizing shareholder value [11][12] - The company is focused on enhancing customer relationships and expanding its customer base, which is expected to contribute to revenue growth [5][11] Leadership Changes - John Brenton was appointed as Chief Financial Officer effective November 1, 2025, expected to play a key role in executing cost reduction initiatives [11]

Core Insights - ODDITY Tech Ltd. reported strong third quarter results for 2025, exceeding guidance in revenue, profit, and earnings per share, and is positioned for continued growth with new brand launches and investments in technology [2][3][4] Financial Performance - Third quarter net revenue reached $148 million, a 24% increase year-over-year from $119 million [4][6] - Gross profit for the third quarter was $106 million, up 27% from $83 million in the same period last year, with a gross margin of 71.6%, an increase of 170 basis points [4][6] - Adjusted EBITDA for the third quarter was $29 million, a 16% increase from $25 million year-over-year [4][6] - Net income for the third quarter was $18 million, consistent with the previous year, while adjusted net income rose to $25 million, a 26% increase from $20 million [4][6] Business Developments - The company successfully launched its new brand, METHODIQ, aimed at transforming the medical care system with advanced technology and precise treatments [2][5] - ODDITY is expanding its ODDITY LABS molecule discovery platform, indicating a focus on innovation and new product development [5] Financial Outlook - ODDITY raised its full-year 2025 financial outlook, projecting net revenue between $806 million and $809 million, representing a year-over-year growth of 24% to 25% [9][10] - The company anticipates a gross margin of approximately 72.5% and adjusted EBITDA between $161 million and $163 million for the full year [10] - For the fourth quarter of 2025, ODDITY expects net revenue between $149 million and $152 million, with a gross margin of approximately 69% [11]

Core Insights - Highwoods Properties, Inc. has completed the acquisition of 6Hundred at Legacy Union, a 24-story Class AA office tower in Charlotte, for a total expected investment of $223 million [1][2] - The property is currently 84% leased with a weighted average lease term exceeding 12 years and encompasses 411,000 square feet [2] - The acquisition will be funded on a leverage-neutral basis over the next six months using proceeds from non-core asset sales, with $37 million in non-core assets sold since October 1, 2025 [3] Investment Details - The total investment includes $8.5 million for planned near-term building improvements and leasing capital expenditures, net of $15.7 million in free rent and other credits received from the seller [1] - The building is designed to achieve LEED gold certification and features in-building parking for 832 vehicles [2] Company Overview - Highwoods Properties, Inc. is a publicly-traded, fully-integrated office real estate investment trust (REIT) focused on owning, developing, acquiring, leasing, and managing properties in major business districts across several cities [5] - The company's mission emphasizes creating exceptional environments and experiences to deliver greater value to customers and shareholders [5]

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta ...

Earnings Release: Tuesday, November 25, 2025, After Market Closes Conference Call and Webcast: Wednesday, November 26, 2025, at 10:00 A.M. Eastern Time MONACO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the Company) (NYSE: SB), an international provider of marine drybulk transportation services, announced today that it will release its results for the third quarter ended September 30, 2025, after the market closes in New York on Tuesday, November 25, 2025. On Wednesday, November 26, 2025, at 10:0 ...

YANGZHOU, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Meihua International Medical Technologies Co., Ltd. (“Meihua” or the “Company”) (Nasdaq: MHUA), reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced that it would effectuate a reverse share split of its outstanding ordinary shares, par value of $0.0005 per share, at a ratio of 1-for-100, and implement its dual-class share structure, to be effective at the open of business on Mo ...